http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Xiaofeng Li,Yaping Tao,Ziyu Hu,Shengli Zhang 한국물리학회 2015 Current Applied Physics Vol.15 No.9
The mechanical and thermodynamic properties, chemical bonding characteristics and electronic structure of Nb2MB2 (M = Mo, W, Re or Os) with a new tetragonal U3Si2-type superstructure (space group P4/ mnc, no. 128) were studied by means of density functional theory calculations. All Nb2MB2 structures studied were demonstrated to be thermodynamically and mechanically stable. The bulk, shear and Young's moduli, Poisson's ratio, Debye temperature and anisotropy factors were derived for ideal polycrystalline Nb2MB2 aggregates. Among these compounds, Nb2WB2 was found to have the highest shear modulus and hardness. The electronic densities of state and electronic localization function analysis revealed the metallicity and strong covalent BeB, NbeB and MB bonding in Nb2MB2. Moreover, these results reveal that the covalence between Nb 4d, M nd (n = 4 for Mo and 5 for W, Re and Os) and B 2p states is the cause of the relatively higher elastic modulus and hardness of the Nb-based compounds. Finally, thermodynamic properties, including the bulk modulus, heat capacity and thermal expansion coefficient of Nb2WB2 were obtained systematically under high temperature and pressure.
Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3
Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226